STAT+: Alnylam says Huntington’s drug shows promise in early study
An experimental Huntington’s drug from Alnylam Pharmaceuticals showed promise in a small study, the company said Friday, suggesting it can partially silence the mutant gene that drives the devastating neurological disorder. Patients